| Moringin — A naturally occurring, rhamnose-containing benzyl isothiocyanate derived from Moringa oleifera, especially its seeds and leaves. Chemically identified as 4-(α-L-rhamnopyranosyloxy)benzyl isothiocyanate, it is also called moringa isothiocyanate-1 (MIC-1) and abbreviated MG. It forms when myrosinase hydrolyzes its glucosinolate precursor, glucomoringin (GMG). Classified as a natural organosulfur compound within the isothiocyanate family, moringin exhibits experimental anticancer, anti-inflammatory, and cytoprotective activities. Its electrophilic isothiocyanate group contributes to redox-sensitive signaling modulation. Moringin is distinct from morin, a flavonol, and from unstandardized Moringa oleifera extracts.
Primary mechanisms (ranked):
- Mitochondrial apoptosis: Promotes mitochondrial membrane depolarization, cytochrome c release, caspase activation, and suppression of anti-apoptotic Bcl-2 family proteins in susceptible cancer cells.
- NF-κB signaling inhibition: Suppresses stimulus-induced p65 nuclear translocation and associated inflammatory and cancer-cell survival signaling.
- Cell-cycle arrest and tumor-suppressor signaling: Increases p53, p21, and Bax in studied models, with S-phase or G2-phase accumulation and reduced proliferation.
- ROS-mediated anticancer activity: Increases intracellular reactive oxygen species in some cancer models, contributing to mitochondrial dysfunction and apoptosis (model-dependent).
- NRF2-associated cytoprotection: Activates antioxidant-response genes including NQO1, HO-1, and GSTP1 in non-cancer inflammatory models. This response may protect normal tissue but could theoretically protect NRF2-dependent tumors (context-dependent).
- Prohibitin and mitochondrial dynamics: Interacts with PHB, DRP1, and SLP2 and alters mitochondrial-associated signaling in breast cancer models; causal contributions require further validation.
- Anti-inflammatory cytokine modulation: Suppresses inducible nitric oxide synthase, nitric oxide production, and inflammatory mediators including IL-1β and IL-6 in stimulated immune-cell models.
- Migration suppression: Reduces migration of experimental breast cancer cells, potentially through NF-κB and mitochondrial-associated signaling; antimetastatic efficacy in humans is unproven.
Bioavailability / PK relevance: Moringin is orally bioaccessible and has demonstrated systemic absorption in rodents. Its rhamnose-containing structure differs from smaller isothiocyanates and may permit circulation of unchanged parent compound. Human pharmacokinetics, oral half-life, tumor distribution, repeated-dose safety, and therapeutic plasma concentrations remain inadequately established. Formation from glucomoringin depends strongly on active myrosinase, preparation conditions, and potentially intestinal microbial metabolism. Heating can inactivate myrosinase, reducing predictable conversion. Standardized preformed moringin or enzyme-activated preparations are preferable for reproducible experimental exposure.
-bioavailability about 62%, and 2 hr half life. Unlike other isothiocyanates, and has favorable bioaccessibility and bioavailability characteristics for a potential therapeutic agent.
In-vitro vs systemic exposure relevance: Cancer-cell responses have been reported at micromolar concentrations, including approximately 1.64–16.4 µM in neuroblastoma studies. Whether comparable free concentrations can be sustained in human tumors following oral consumption is unknown. Rat absorption data do not establish human exposure equivalence. Cancer experiments using high concentrations or prolonged continuous incubation must not be interpreted as evidence of achievable oral anticancer activity.
Clinical evidence status: Preclinical — cell-based studies and limited animal antitumor experiments. Small human cancer studies: none established. Randomized controlled cancer trials: none established. Clinical adjunct use: investigational only. Moringin is not an approved anticancer therapy, and no validated human anticancer dosage or therapeutic regimen exists.
Cancer-Related Mechanisms
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Mitochondrial apoptosis |
Membrane potential ↓; cytochrome c ↑; Bax ↑; Bcl-2 ↓; Bcl-xL ↓; caspase-3/7/9 activation ↑ |
Apoptosis ↔ (model-dependent) |
R, G |
Apoptotic cell death ↑ |
Demonstrated in breast cancer and neuroblastoma cell models. Caspase involvement varies by model; selective sparing of normal cells is not established broadly. |
| 2 |
NF-κB p65 survival signaling |
p65 nuclear translocation ↓; NF-κB activity ↓ |
Inflammatory NF-κB signaling ↓ |
R, G |
Pro-survival and inflammatory signaling ↓ |
Supported by breast cancer, neuroblastoma, and myeloma experiments. One of the most consistent mechanistic findings for purified moringin. |
| 3 |
Cell-cycle arrest and p53 p21 axis |
p53 ↑; p21 ↑; S/G2 accumulation ↑; proliferation ↓ |
Proliferation ↔ (model-dependent) |
G |
Cell-cycle progression ↓ |
Neuroblastoma and myeloma studies show cell-cycle disruption. Specific phase distribution and p53 dependence vary by cancer model. |
| 4 |
Mitochondrial ROS increase |
ROS ↑; oxidative stress ↑; mitochondrial dysfunction ↑ |
Oxidative stress ↓ (context-dependent) |
P, R, G |
Redox-mediated apoptosis |
ROS induction demonstrated in breast cancer cells. Protective antioxidant activity in non-cancer models does not demonstrate tumor-selective oxidative toxicity. |
| 5 |
Prohibitin and mitochondrial dynamics |
PHB ↑; interactions with DRP1 and SLP2; mitochondrial signaling altered |
Not established |
R, G |
Mitochondrial stress and survival modulation |
Reported in MCF-7 and MDA-MB-231 breast cancer cells. PHB has context-dependent functions; direct binding or expression changes alone do not establish pathway causality. |
| 6 |
Antiapoptotic survival proteins |
Survivin ↓; Bcl-2 ↓; Bcl-xL ↓ |
Not established |
G |
Resistance to apoptosis ↓ |
Observed in breast cancer cells; overlaps functionally with mitochondrial apoptosis but identifies potentially important molecular targets. |
| 7 |
Cancer cell migration |
Migration ↓; invasion signaling potentially ↓ |
Not established |
G |
Motility ↓ |
Migration reduction reported in breast cancer cell models. In vivo metastasis prevention by purified moringin remains unproven. |
| 8 |
NRF2 antioxidant response |
NRF2 activity ↔ or ↑ (context-dependent) |
NRF2 target genes ↑; NQO1 ↑; HO-1 ↑; GSTP1 ↑ |
R, G |
Detoxification and cytoprotection ↑ |
Demonstrated principally in inflammatory non-cancer models. NRF2 activation may contribute to chemoprevention but could support survival of some established cancers. |
| 9 |
iNOS nitric oxide and cytokine signaling |
Not established consistently for purified moringin |
iNOS ↓; NO ↓; IL-1β ↓; IL-6 ↓ in stimulated immune cells |
R, G |
Inflammation ↓ |
MIC-1 suppresses inflammatory responses in macrophage models. These findings should not be interpreted as direct inhibition of the same pathways in tumors. |
| 10 |
Long noncoding RNA regulation |
Selected lncRNA expression altered |
Not established |
G |
Transcriptional regulatory changes |
Observed in breast cancer experiments; the functional contribution of individual lncRNAs to anticancer activity remains incompletely resolved. |
| 11 |
Clinical Translation Constraint |
Micromolar experimental exposure; clinical tumor concentrations unknown |
Short-term animal safety data; long-term human safety unknown |
G |
Clinical applicability undetermined |
Conversion from glucomoringin depends on myrosinase. Rat oral bioavailability does not establish human tumor exposure. A 14-day rat study reported a NOAEL of 100 mg/kg/day MIC-1 from standardized seed extract, with mortality at substantially higher exposure. No validated human anticancer regimen exists. |
P: 0–30 min R: 30 min–3 hr G: >3 hr
|